Status:
RECRUITING
PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS
Lead Sponsor:
University Hospital, Brest
Conditions:
Inflammatory Rheumatism
Polymyalgia Rheumatica
Eligibility:
All Genders
18-85 years
Brief Summary
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients wit...
Eligibility Criteria
Inclusion
- Life expectancy \> 1 year.
- Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for the treatment of an inflammatory rheumatic disease.
- Initial treatment or relapse.
- Previsional treatment duration \> 3 months.
Exclusion
- Unable to consent.
- Previous corticosteroid therapy in the last 3 months at a significant dosage (\> 5 mg per day).
Key Trial Info
Start Date :
March 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 18 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04664465
Start Date
March 18 2021
End Date
March 18 2026
Last Update
February 11 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Angers
Angers, France, 49933
2
CHRU de Brest
Brest, France, 29609
3
CHD Vendée
La Roche-sur-Yon, France, 85925
4
CH Le Mans
Le Mans, France, 72000